These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 35131966)

  • 1. Development 68Ga trastuzumab Fab and bioevaluation by PET imaging in HER2/neu expressing breast cancer patients.
    Rathore Y; Shukla J; Laroiya I; Deep A; Lakhanpal T; Kumar R; Singh H; Bal A; Singh G; Gopal Thakur K; Mittal BR
    Nucl Med Commun; 2022 Apr; 43(4):458-467. PubMed ID: 35131966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Breast Cancer Using 177 Lu-Labeled Trastuzumab and Trastuzumab Fragment : First-in-Human Clinical Experience.
    Rathore Y; Lakhanpal T; Chakraborty S; Chakravarty R; Mittal BR; Irrinki RNS; Laroiya I; Kaur K; Shukla J
    Clin Nucl Med; 2024 Jun; 49(6):e258-e265. PubMed ID: 38579266
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Kwon LY; Scollard DA; Reilly RM
    Mol Pharm; 2017 Feb; 14(2):492-501. PubMed ID: 28049295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MANOTA: a promising bifunctional chelating agent for copper-64 immunoPET.
    Moreau M; Poty S; Vrigneaud JM; Walker P; Guillemin M; Raguin O; Oudot A; Bernhard C; Goze C; Boschetti F; Collin B; Brunotte F; Denat F
    Dalton Trans; 2017 Oct; 46(42):14659-14668. PubMed ID: 28861553
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Suman SK; Mukherjee A; Pandey U; Chakraborty A; Rakshit S; Tawate M; Sarma HD
    Cancer Biother Radiopharm; 2023 Feb; 38(1):38-50. PubMed ID: 36413344
    [No Abstract]   [Full Text] [Related]  

  • 6. Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [(99m)Tc]-HYNIC-trastuzumab (Herceptin) Fab fragments.
    Tang Y; Scollard D; Chen P; Wang J; Holloway C; Reilly RM
    Nucl Med Commun; 2005 May; 26(5):427-32. PubMed ID: 15838425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using (111)In-trastuzumab (Herceptin) Fab fragments.
    Tang Y; Wang J; Scollard DA; Mondal H; Holloway C; Kahn HJ; Reilly RM
    Nucl Med Biol; 2005 Jan; 32(1):51-8. PubMed ID: 15691661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PET imaging of CD105/endoglin expression with a ⁶¹/⁶⁴Cu-labeled Fab antibody fragment.
    Zhang Y; Hong H; Orbay H; Valdovinos HF; Nayak TR; Theuer CP; Barnhart TE; Cai W
    Eur J Nucl Med Mol Imaging; 2013 May; 40(5):759-67. PubMed ID: 23344138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A kit to prepare (111)In-DTPA-trastuzumab (Herceptin) Fab fragments injection under GMP conditions for imaging or radioimmunoguided surgery of HER2-positive breast cancer.
    Scollard DA; Chan C; Holloway CM; Reilly RM
    Nucl Med Biol; 2011 Jan; 38(1):129-36. PubMed ID: 21220136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging.
    Dijkers EC; Kosterink JG; Rademaker AP; Perk LR; van Dongen GA; Bart J; de Jong JR; de Vries EG; Lub-de Hooge MN
    J Nucl Med; 2009 Jun; 50(6):974-81. PubMed ID: 19443585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ImmunoPET of tissue factor expression in triple-negative breast cancer with a radiolabeled antibody Fab fragment.
    Shi S; Hong H; Orbay H; Graves SA; Yang Y; Ohman JD; Liu B; Nickles RJ; Wong HC; Cai W
    Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1295-303. PubMed ID: 25801992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer.
    Xavier C; Vaneycken I; D'huyvetter M; Heemskerk J; Keyaerts M; Vincke C; Devoogdt N; Muyldermans S; Lahoutte T; Caveliers V
    J Nucl Med; 2013 May; 54(5):776-84. PubMed ID: 23487015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of
    Woo SK; Jang SJ; Seo MJ; Park JH; Kim BS; Kim EJ; Lee YJ; Lee TS; An GI; Song IH; Seo Y; Kim KI; Kang JH
    J Nucl Med; 2019 Jan; 60(1):26-33. PubMed ID: 29777007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noninvasive Detection of HER2 Expression in Gastric Cancer by
    Guo X; Zhu H; Zhou N; Chen Z; Liu T; Liu F; Xu X; Jin H; Shen L; Gao J; Yang Z
    Mol Pharm; 2018 Nov; 15(11):5174-5182. PubMed ID: 30251865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer.
    Heskamp S; Laverman P; Rosik D; Boschetti F; van der Graaf WT; Oyen WJ; van Laarhoven HW; Tolmachev V; Boerman OC
    J Nucl Med; 2012 Jan; 53(1):146-53. PubMed ID: 22173842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with
    Al-Saden N; Lam K; Chan C; Reilly RM
    Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of [
    Pougoue Ketchemen J; Njotu FN; Babeker H; Ahenkorah S; Tikum AF; Nwangele E; Henning N; Cleeren F; Fonge H
    Eur J Nucl Med Mol Imaging; 2024 Jun; 51(7):2070-2084. PubMed ID: 38376808
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.